Syneron Candela Achieves Approval to Market Its ALEX II System in Japan For Treatment of Benign Dermal Lesions
PR Newswire Association LLC |
A special configuration of Candela's successful Alex TriVantage® platform that has been customized for the Japanese market, the ALEX II is a single wavelength Q-switched alexandrite laser designed to treat congenital pigmented lesions and tattoos. It is the second generation of the 755nm Q-switched laser system popular in
"In comparison to Q-switched ruby lasers and Q-switched Nd:YAG lasers which are also commonly used in
There are approximately 500 ALEXLAZR systems in
Known to be an exacting process, approval from the MHLW will also facilitate health insurance payments to physicians and patients allowing for certain medical conditions to be reimbursed. Patients with congenital pigmented lesions, such as Nevus of Ota, ectopic Mongolian spots and traumatic tattoos, will now be covered under
"We are honored that the ALEX II 755 nm Q-switched laser system has been approved for use in
About
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that
Contacts:
Logo - http://photos.prnewswire.com/prnh/20120528/535447
SOURCE
Wordcount: | 788 |
Horrible ending for a historic local business
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News